Protective effects of intranasal erythropoietin on chronic cerebral ischemia in rats

Abstract

Abstract: AIM: To investigate the protective effects of recombinant human erythropoietin (rhEPO) administrated intranasally on chronic cerebral ischemia in rats.METHODS: Focal cerebral ischemia in rats were induced by middle cerebral artery occlusion (MCAO). Drugs were injected intranasally or intraperitoneally 30 min before and 2 h after operation. From the second day, they were administrated qod for 2 weeks. In addition to neurological deficit and inclined board test during 35 d, we detected infarct volume and the survival neuron density in the ischemic brain tissue 35 d after operation.RESULTS: rhEPO (24, 48 U) intranasally, edaravone and rhEPO i.p. (5000 U/kg) significantly attenuated neurological deficit and infarct volume, increased the angle in the board test and the survival neuron density in the border of ischemia.CONCLUSION: rhEPO intranasally demonstrates protective effect on chronic cerebral ischemia in rats. Especially the effective dosage of rhEPO intranasally far is smaller than intraperitoneally.

Key words: Recombinant human erythropoietin (rhEPO), Intranasal administration, Cerebral ischemia, Rat

CLC Number:

R965.2

YE Yi-lu, ZHANG Qi, JI Hua, ZHANG Jian-ting, HUANG Chun-yan, YU Yue-ping, RAO Yan. Protective effects of intranasal erythropoietin on chronic cerebral ischemia in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(9): 997-1001.

References

[1] Zuppa AA, Alighieri G, Calabrese V, et al. Recombinant human erythropoietin in the prevention of late anemia in intrauterine transfused neonates with Rh-isoimmunization[J]. J Pediatr Hematol Oncol, 2010, 32(3): 95-101.
[2] Kim MK, Baek KH, Lim DJ, et al. Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure[J]. J Diabetes Complications, 2010, 24(2): 90-95.
[3] Chu K, Jung KH, Lee ST, et al. Erythropoietin reduces epileptogenic processes following status epilepticus[J]. Epilepsia, 2008, 49(10): 1723-1732.
[4] Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury[J]. Proc Natl Acad Sci USA, 2000, 97(19): 10526-10531.
[5] Kaptanoglu E, Solaroglu I, Okutan O, et al. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings[J]. Neurosurg Rev, 2004, 27(2): 113-120.
[6] Yu YP, Xu QQ, Zhang Q, et al. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia[J]. Neurosci Lett, 2005, 387(1): 5-10.
[7] Solaroglu I, Solaroglu A, Kaptanoglu E, et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain[J]. Childs Nerv Syst, 2003, 19(1): 19-22.
[8] Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects[J]. Int J Pharm, 2007, 337(1/2): 1-24.
[9] 胡怀强,王新陆,周永红,等. 逍遥滴鼻液对实验性偏头痛模型大鼠c-fos基因表达的影响[J].中国临床药理学与治疗学,2004,9(7):774-777.
[10] Zhang WP, Wei EQ, Mei RH, et al. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats[J]. Acta Pharmacol Sin, 2002, 23(10): 871-877.
[11] Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination[J]. Stroke, 1986, 17(3): 472-476.
[12] Yonemori F, Yamaguchi T, Yamada H, et al. Evaluation of a motor deficit after chronic focal cerebral ischemia in rats[J]. J Cereb Blood Flow Metab, 1998, 18(10): 1099-1106.
[13] Buemi M, Cavallaro E, Floccari F, et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection[J]. Clin Sci (Lond), 2002, 103(3): 275-282.
[14] Shi Z, Zhang Q, Jiang X. A novel method to calculate the extent and amount of drug transported into CSF after intranasal administration[J]. Int J Pharm, 2005, 289(1/2): 159-166.
[15] Yan YL, Ye Y, Zhou LL. Study on brain pharmacokinetics of tetramethylpyrazine phosphate after intranasal administration[J]. Traditional Chinese Drug Research & Clinical Pharmacology, 2009, 20 (7):548-550.
[16] Alcala-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS[J]. J Drug Target, 2010, 18(3): 179-190.
[17] Dyker AG, Lees KR. Duration of neuroprotective treatment for ischemic stroke[J]. Stroke, 1998, 29(2): 535-542.
[18] Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure[J]. NeuroRx, 2004, 1(1): 36-45.
[19] Okutan O, Solaroglu I, Beskonakli E, et al. Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats[J]. J Clin Neurosci, 2007, 14(4): 364-368.
[20] Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats[J]. Stroke, 2004, 35(7): 1732-1737.